Precision Business Insights
Portfolio

 

Kidney Cancer Diagnostics Market

: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Kidney Cancer Diagnostics Market: By Type of Condition (Renal Cell Carcinoma , Urothelial Carcinoma, Sarcoma, Wilms Tumor, Lymphoma), Type of Test (Ultrasound, CT Scan, MRI, Radioisotope Scan, Tissue Biopsy, Intravenous Pyelogram (IVP), Uninalysis, Blood Chemistry Studies), End user (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Geography 

 

Kidney Cancer Diagnostics Market Size:

 

Kidney Cancer Diagnostics market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

 

Market Outline:

Kidney cancer begins when healthy cells in kidneys change and grow abnormally forming a mass called renal cortical tumor. A tumor can be malignant, indolent or benign.  There are three main types of kidney cancers amongst renal cell cancer is the most common type of cancer in adults and wilms tumors are common in children.

 

Market Dynamics:

Increase in the prevalence and incidence of kidney cancer and growing geriatric population propels the growth of the Kidney Cancer Diagnostics market globally. Furthermore increase in awareness regarding kidney cancers, drastic lifestyle changes, government initiatives drives the growth of Kidney Cancer Diagnostics market globally. Moreover technological advancements, advanced healthcare services and increase in healthcare expenditure also propels the market growth of endometrial cancer diagnostics globally. However, rise in number of patient expirations, stringent regulatory framework, high cost associated with the tests and treatments, adverse effects and lack of awareness about innovative technologies may hinder the growth of the market globally.

 

Market Scope:

Kidney Cancer Diagnostics market is segmented based on the type of condition, type of test, end user and geographical regions

Based on the type of condition

  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Sarcoma
  • Wilms Tumor
  • Lymphoma

Based on the type of test

  • Ultrasound
  • CT Scan
  • MRI
  • Radioisotope Scan
  • Tissue Biopsy
  • Intravenous Pyelogram (IVP)
  • Uninalysis
  • Blood Chemistry Studies

Based on the end user

  • Diagnostic Centers
  • Hospitals
  • Ambulatory Surgical Centers

Based on the geographical regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

 

Market Summary:

Early diagnosis of kidney cancer is very important for the successful treatment. As with most types of cancer, the earlier the tumor is discovered the better the patient’s chances of survival, as tumors discovered in early stages often respond well to treatment. Kidney cancer survival rates are high in such cases. The global kidney cancer diagnostics market displays high competition among market players as it is a very highly consolidated market. Major market player are investing high capitals on R&D and generating many strategies such as new product launches and developments, geographical expansions, collaborations and acquisitions to strengthen their market position in global kidney cancers diagnostics market.

 

Regional Analysis:

Geographically, global Kidney Cancer Diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America Kidney Cancer Diagnostics market and Europe Kidney Cancer Diagnostics market is growing due to increase in the prevalence of  kidney cancer cases, increase in ageing population, presence of favorable reimbursement policies, high healthcare expenditure, well established healthcare infrastructure. Asia Pacific market also growing at a significant rate, which is attributed to increase health awareness regarding kidney cancer, growing economy of emerging countries. . Latin America market and Middle East and Africa market are haing lucrative growth oppurtunities owing to the geographical expansion by market players in those regions and increase in the expenditure of healthcare.

 

Competition Assessment:

Some of the players in the global Kidney Cancer Diagnostics market include:

  • Ariad Pharmaceuticals, Inc. (U.S)
  • Merck & Co., Inc. (U.S)
  • Abbott Laboratories (U.S)
  • Siemens Healthcare Inc. (Germany)
  • Hoffman-La Roche Ltd. (Switzerland)
  • Becton, Dickinson & Co. (U.S)
  • GlaxoSmithKline Plc., etc. (UK)

 

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Ariad Pharmaceuticals, Inc. (U.S)
  • Merck & Co., Inc. (U.S)
  • Abbott Laboratories (U.S)
  • Siemens Healthcare Inc. (Germany)
  • Hoffman-La Roche Ltd. (Switzerland)
  • Becton, Dickinson & Co. (U.S)
  • GlaxoSmithKline Plc., etc. (UK)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials